Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). 3,4-DAP is used to decrease the muscle weakness associated with
LEMS and hopefully will decrease the need for prednisone and all other therapies that were
previously required to control symptoms. How long a patient will take 3,4 DAP depends upon if
he/she is seeing benefits from the medication or experiencing side effects that will prevent
them from continuation in the study.